Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin to Present at the Jefferies 2020 Virtual Healthcare Conference
SAN DIEGO , May 27, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube , Ph.D., chief executive officer, will present at the Jefferies 2020 Virtual Healthcare Conference on Wednesday, June 3, 2020 at 2:30 p.m. ET . A live webcast of the presentation will be
View HTML
Toggle Summary Retrophin Reports First Quarter 2020 Financial Results
Enrollment continues in the pivotal DUPLEX and PROTECT studies of sparsentan DUPLEX Study of sparsentan in FSGS enrolled first 190 patients required for interim proteinuria analysis Net product sales increased to $47.8 million SAN DIEGO , May 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc.
View HTML
Toggle Summary Retrophin to Report First Quarter 2020 Financial Results
SAN DIEGO , April 27, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report first quarter 2020 financial results on Monday, May 11, 2020 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin Appoints Suzanne L. Bruhn, Ph.D. to Board of Directors
Dr. Bruhn brings more than 20 years of biopharmaceutical experience to the Retrophin Board SAN DIEGO , April 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Suzanne L. Bruhn , Ph.D. to the Company’s Board of Directors, effective immediately. Dr.
View HTML
Toggle Summary Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
Topline data from 36-week proteinuria endpoint anticipated in first quarter of 2021 SAN DIEGO , March 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 190 patients have been enrolled in the pivotal Phase 3 DUPLEX Study evaluating the safety and efficacy of
View HTML
Toggle Summary Retrophin Recognizes Rare Disease Day 2020 and the Importance of Working Together Toward More Equitable Access to Care
SAN DIEGO , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), and rare disease advocates and patients worldwide to recognize February 29 as Rare Disease Day 2020.
View HTML
Toggle Summary Retrophin Reports Fourth Quarter and Full Year 2019 Financial Results
Pivotal DUPLEX and PROTECT studies of sparsentan enrolling towards topline readouts to support potential NDA and CMA filings Full year 2019 net product sales of $175 million SAN DIEGO , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its fourth quarter and full year
View HTML
Toggle Summary Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming investor conferences in February and March: 9th Annual SVB Leerink Global Healthcare Conference Date: Wednesday, February 26, 2020 Time: 9:30
View HTML
Toggle Summary Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Feb. 13, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that on February 10, 2020 , the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 22,500 shares of its common stock to three new employees and
View HTML
Toggle Summary Retrophin to Report Fourth Quarter and Full Year 2019 Financial Results
SAN DIEGO , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2019 financial results on Monday, February 24, 2020 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss
View HTML